Continuous systemic infusion refractory prostatic cancer patients metastatic prostatic cancer ambulatory basis continuous infusion day chronic indwelling central venous catheter patients symptomatic progressive disease previous standard therapies Partial remission patients stable disease progressive disease mean duration benefit stable disease patients months Improvement pain ECOG performance status patients responding stable disease categories Forty percent patients significant drug toxicity treatment interruption necessary stomatitis patients hand/foot syndrome patients diarrhea patient significant myelosuppression significant organ toxicities Continuous systemic venous infusion significant palliative effect patients symptomatic refractory carcinoma prostate 